Recent Company News

• 08:08 AM ET May 05, 2026
  

  CVS Caremark expands biosimilar adoption through formulary updates ($82.01, 0.00)

• 05:45 PM ET May 04, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 02:00 PM ET May 04, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 27-Apr

• 10:33 AM ET May 04, 2026
  

  StreetAccount M&A Summary: Week of 27-Apr

• 08:48 AM ET May 04, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:01 AM ET May 04, 2026
  

  Rallybio to receive $50.0M termination fee in connection with Candid's terminated of prior merger agreement and permitted alternative agreement with UCB - 8-K ($9.41, 0.00)

• 04:47 PM ET May 03, 2026
  

  UCB to acquire Candid Therapeutics at total transaction value of up to $2.2B (€231.20, 0.00)

• 01:02 AM ET May 01, 2026
  

  UCB announces acquisition of IMIDomics' Patient Insight Business; price not disclosed (€231.20, 0.00)

• 04:07 AM ET Apr 28, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:00 PM ET Apr 20, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 13-Apr